Otoshi et al., 2019 - Google Patents
Possible biomarkers for cancer immunotherapyOtoshi et al., 2019
View HTML- Document ID
- 5004983492797200280
- Author
- Otoshi T
- Nagano T
- Tachihara M
- Nishimura Y
- Publication year
- Publication venue
- Cancers
External Links
Snippet
Immune checkpoint inhibitors (ICIs) have drastically changed the clinical care of cancer. Although cancer immunotherapy has shown promise in various types of malignancies, thus far, the proportion of patients who can benefit from ICIs is relatively small. Immune-related …
- 239000000090 biomarker 0 title abstract description 36
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Otoshi et al. | Possible biomarkers for cancer immunotherapy | |
El-Sayes et al. | Tumor heterogeneity: a great barrier in the age of cancer immunotherapy | |
Onoi et al. | Immune checkpoint inhibitors for lung cancer treatment: a review | |
Temraz et al. | Gut microbiome: a promising biomarker for immunotherapy in colorectal cancer | |
Tunger et al. | The evolving landscape of biomarkers for anti-PD-1 or anti-PD-L1 therapy | |
Wojas-Krawczyk et al. | Beyond PD-L1 markers for lung cancer immunotherapy | |
Cesano et al. | Bringing the next generation of immuno-oncology biomarkers to the clinic | |
Pagni et al. | Targeting immune-related biological processes in solid tumors: we do need biomarkers | |
Kaderbhaï et al. | The role of molecular profiling to predict the response to immune checkpoint inhibitors in lung cancer | |
Shindo et al. | Novel biomarkers for personalized cancer immunotherapy | |
Valenti et al. | Precision medicine and melanoma: multi-omics approaches to monitoring the immunotherapy response | |
Olbryt et al. | Biological factors behind melanoma response to immune checkpoint inhibitors | |
Mulet-Margalef et al. | Challenges and therapeutic opportunities in the dMMR/MSI-H colorectal cancer landscape | |
Cabel et al. | Limited sensitivity of circulating tumor DNA detection by droplet digital PCR in non-metastatic operable gastric cancer patients | |
Sesma et al. | From tumor mutational burden to blood T cell receptor: looking for the best predictive biomarker in lung cancer treated with immunotherapy | |
Cimas et al. | Genomic mapping identifies mutations in RYR2 and AHNAK as associated with favorable outcome in basal-like breast tumors expressing PD1/PD-L1 | |
Ros et al. | Immunotherapy for colorectal cancer with high microsatellite instability: the ongoing search for biomarkers | |
Moisseev et al. | Transcriptomic and genomic testing to guide individualized treatment in chemoresistant gastric cancer case | |
Busse et al. | Immunoprofiling in neuroendocrine neoplasms unveil immunosuppressive microenvironment | |
Ulase et al. | Gastric carcinomas with stromal B7-H3 expression have lower intratumoural CD8+ T cell density | |
Sillo et al. | The gut microbiome, microsatellite status and the response to immunotherapy in colorectal cancer | |
Narasimhan et al. | Profiling of adipose and skeletal muscle in human pancreatic cancer cachexia reveals distinct gene profiles with convergent pathways | |
Thouvenin et al. | Complete response in metastatic clear cell renal cell carcinoma patients treated with immune-checkpoint inhibitors: remission or healing? How to improve patients’ outcomes? | |
Tang et al. | Identification of CD73 as a novel biomarker encompassing the tumor microenvironment, prognosis, and therapeutic responses in various cancers | |
Emmelot et al. | SARS-CoV-2 omicron BA. 4/BA. 5 mutations in spike leading to T cell escape in recently vaccinated individuals |